ZyVersa Therapeutics Ownership 2024 | Who Owns ZyVersa Therapeutics Now?

Overview RevenueFinancials Chart

Institutional Ownership

1.57%

Insider Ownership

0.61%

Retail Ownership

97.82%

Institutional Holders

6.00

ZyVersa Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
GOLDMAN SACHS GROUP INC	1.15%	-	103,471	39,213	61.02%	199,699,000	Mar 31, 2023
VANGUARD GROUP INC	0.19%	-	16,894	16,894	100.00%	32,605,000	Mar 31, 2023
WINTHROP ADVISORY GROUP LLC	0.15%	0.00%	13,361	13,361	100.00%	26,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	4,663	4,663	100.00%	9,000	Mar 31, 2023
UBS GROUP AG	0.04%	-	3,282	3,282	100.00%	6,334,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	28	28	100.00%	54,000	Mar 31, 2023
CSS LLC/IL	-	-	-	-14,648	-100.00%	-	Mar 31, 2023

ZyVersa Therapeutics's largest institutional shareholder is GOLDMAN SACHS GROUP INC, holding 1.15% of the company's total share outstanding, currently valued at $199.70M. The top 10 institutional shareholders own together 1.57% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WINTHROP ADVISORY GROUP LLC	0.15%	0.00%	13,361	13,361	100.00%	26,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	4,663	4,663	100.00%	9,000	Mar 31, 2023
GOLDMAN SACHS GROUP INC	1.15%	-	103,471	39,213	61.02%	199,699,000	Mar 31, 2023
UBS GROUP AG	0.04%	-	3,282	3,282	100.00%	6,334,000	Mar 31, 2023
VANGUARD GROUP INC	0.19%	-	16,894	16,894	100.00%	32,605,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	28	28	100.00%	54,000	Mar 31, 2023
CSS LLC/IL	-	-	-	-14,648	-100.00%	-	Mar 31, 2023

The largest ZyVersa Therapeutics shareholder by % of total assets is WINTHROP ADVISORY GROUP LLC. The company owns 13.36K shares of ZyVersa Therapeutics (ZVSA), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
GOLDMAN SACHS GROUP INC	1.15%	-	103,471	39,213	61.02%	199,699,000	Mar 31, 2023
VANGUARD GROUP INC	0.19%	-	16,894	16,894	100.00%	32,605,000	Mar 31, 2023
WINTHROP ADVISORY GROUP LLC	0.15%	0.00%	13,361	13,361	100.00%	26,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	4,663	4,663	100.00%	9,000	Mar 31, 2023
UBS GROUP AG	0.04%	-	3,282	3,282	100.00%	6,334,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	28	28	100.00%	54,000	Mar 31, 2023
CSS LLC/IL	-	-	-	-14,648	-100.00%	-	Mar 31, 2023

As of Mar 31 2023, ZyVersa Therapeutics's largest institutional buyer is GOLDMAN SACHS GROUP INC. The company purchased 39.21K stocks of ZVSA, valued at $199.70M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
CSS LLC/IL	-	-	-	-14,648	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	28	28	100.00%	54,000	Mar 31, 2023
UBS GROUP AG	0.04%	-	3,282	3,282	100.00%	6,334,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	4,663	4,663	100.00%	9,000	Mar 31, 2023
WINTHROP ADVISORY GROUP LLC	0.15%	0.00%	13,361	13,361	100.00%	26,000	Mar 31, 2023
VANGUARD GROUP INC	0.19%	-	16,894	16,894	100.00%	32,605,000	Mar 31, 2023
GOLDMAN SACHS GROUP INC	1.15%	-	103,471	39,213	61.02%	199,699,000	Mar 31, 2023

As of Mar 31 2023, ZyVersa Therapeutics's biggest institutional seller is CSS LLC/IL. The company sold -14.65K shares of ZVSA, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
VANGUARD GROUP INC	0.19%	-	16,894	16,894	100.00%	32,605,000	Mar 31, 2023
WINTHROP ADVISORY GROUP LLC	0.15%	0.00%	13,361	13,361	100.00%	26,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.05%	0.00%	4,663	4,663	100.00%	9,000	Mar 31, 2023
UBS GROUP AG	0.04%	-	3,282	3,282	100.00%	6,334,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	28	28	100.00%	54,000	Mar 31, 2023

ZyVersa Therapeutics's largest new institutional shareholder by number of shares is VANGUARD GROUP INC, purchased 16.89K shares, valued at $32.60M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
CSS LLC/IL	-	-	-	-14,648	-100.00%	-	Mar 31, 2023

ZyVersa Therapeutics's largest sold out institutional shareholder by shares sold is CSS LLC/IL, sold -14.65K shares, valued at -, as of undefined.

ZyVersa Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
FIDELITY CONCORD STREET TRUST	0.00%	123,130	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	17,194	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	3,520	3,520	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	493	-493	-50.00%	Mar 31, 2024

ZyVersa Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY CONCORD STREET TRUST", owning 123.13K shares, compromising 0.00% of its total assets.

ZyVersa Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 23	6	200.00%
31 Dec, 22	2	-

As of 31 Mar 23, 6 institutions are holding ZyVersa Therapeutics's shares, representing an increase of 200.00% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 23	141,699	79.58%
31 Dec, 22	78,906	-

ZyVersa Therapeutics (ZVSA) has 141.70K shares outstanding as of 31 Mar 23, up 79.58% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 23	1.57%	-
31 Dec, 22	-	-

As of 31 Mar 23, ZyVersa Therapeutics is held by 1.57% institutional shareholders, representing a 0.00% growth compared to 31 Dec 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 23	1	-
31 Dec, 22	-	-

1 institutional shareholders have increased their position in ZVSA stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 23	-	-
31 Dec, 22	-	-

- institutional shareholders have reduced their position in ZVSA stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 23	6	200.00%	141,699	79.58%	1.57%	-	1	-	-	-
31 Dec, 22	2	-	78,906	-	-	-	-	-	-	-

ZyVersa Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Jan 26, 2023	Guzman Pablo A.	officer	Chief Medical Officer		Sell	9,015	$6.90	$62.20K	-
Jan 26, 2023	Guzman Pablo A.	officer	Chief Medical Officer		Sell	-	-	-	26,021

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jul 18, 2024	Cashmere Karen A.	director	-	A-Award	Buy	572	$152.46	$87.21K	572
Jul 18, 2024	Wolfe Peter	officer	Chief Financial Officer	A-Award	Buy	715	$152.46	$109.01K	715
Jul 18, 2024	Glover Stephen C.	director, officer	Chief Executive Officer	A-Award	Buy	1,627	$152.46	$248.05K	1,627
Jul 18, 2024	Park Min-Chul	director	-	A-Award	Buy	132	$152.46	$20.12K	132
Jul 18, 2024	Freitag Gregory Gene	director	-	A-Award	Buy	132	$152.46	$20.12K	132
Jul 18, 2024	SAPIRSTEIN JAMES	director	-	A-Award	Buy	132	$152.46	$20.12K	132
Jul 18, 2024	Finizio Robert G	director	-	A-Award	Buy	132	$152.46	$20.12K	132
Aug 03, 2023	INCON Co., Ltd.	10 percent owner			Buy	-	-	-	-
Jan 26, 2023	Guzman Pablo A.	officer	Chief Medical Officer	A-Award	Buy	100,000	-	-	100,000
Jan 26, 2023	Guzman Pablo A.	officer	Chief Medical Officer		Sell	9,015	$6.90	$62.20K	-
Jan 26, 2023	Guzman Pablo A.	officer	Chief Medical Officer		Sell	-	-	-	26,021
Jan 17, 2023	SAPIRSTEIN JAMES	-	-		Buy	-	-	-	-
Jan 17, 2023	SAPIRSTEIN JAMES	director			Buy	-	-	-	-
Jan 17, 2023	Rupalla Katrin	-	-		Buy	-	-	-	-
Jan 17, 2023	Rupalla Katrin	director			Buy	-	-	-	-
Jan 17, 2023	Freitag Gregory Gene	-	-		Buy	-	-	-	-
Jan 17, 2023	Freitag Gregory Gene	director			Buy	-	-	-	-
Dec 20, 2022	Wolfe Peter	officer	Chief Financial Officer	A-Award	Buy	3,000	$2.88	$8.64K	44,585
Dec 16, 2022	INCON Co., Ltd.	director	-	A-Award	Buy	1,497,199	-	-	1,497,199
Dec 16, 2022	INCON Co., Ltd.	director	-	A-Award	Buy	450,702	-	-	450,702

The last insider sell of ZyVersa Therapeutics's stock was made by Guzman Pablo A. on Jan 26 2023, selling 9,015 shares at $6.90 per share (valued at $62.20K).

ZyVersa Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2023	1	1	100.00%
Q4 2022	-	1	-
Q1 2022	7	6	116.67%

1 total buy trades, and 1 total sell trades (buy/sell ratio of 1.00%) were made by ZyVersa Therapeutics's insiders, as of Q1 2023.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2023	-	-	-
Q4 2022	-	-	-
Q1 2022	-	-	-

As of Q1 2023, Insider owners conducted 0 open market buy trades and 0 open market sell trades of ZyVersa Therapeutics's stocks.

ZyVersa Therapeutics Peer Ownership

Ticker	Company
CNSP	CNS Pharmaceuticals, Inc.
VECT	VectivBio Holding AG
VIRI	Virios Therapeutics, Inc.
AVRO	AVROBIO, Inc.
EFTR	eFFECTOR Therapeutics, Inc.
IMMX	Immix Biopharma, Inc.
HEPA	Hepion Pharmaceuticals, Inc.
ZURA	Zura Bio Limited

ZVSA Ownership FAQ

Who Owns ZyVersa Therapeutics?

ZyVersa Therapeutics is owned by institutional shareholders (1.57%), insiders (0.61%), and public (97.82%). The largest institutional shareholder of ZyVersa Therapeutics is GOLDMAN SACHS GROUP INC (1.15% of total shares) and the top mutual fund owner is FIDELITY CONCORD STREET TRUST (0.00% of total shares).

Who are the major institutional shareholders of ZyVersa Therapeutics?

ZyVersa Therapeutics's major institutional shareholders are GOLDMAN SACHS GROUP INC, VANGUARD GROUP INC, WINTHROP ADVISORY GROUP LLC, TOWER RESEARCH CAPITAL LLC (TRC), and UBS GROUP AG. The top five shareholders own together 1.57% of the company's share outstanding.

How many ZyVersa Therapeutics shareholders are there?

As of Mar 2023, there are 6 institutional shareholders of ZyVersa Therapeutics.

What percentage of ZyVersa Therapeutics is owned by GOLDMAN SACHS GROUP INC?

GOLDMAN SACHS GROUP INC owns 103.47K shares of ZyVersa Therapeutics, representing 1.15% of the company's total shares outstanding, valued at $199.7M (as of Mar 2023).

What percentage of ZyVersa Therapeutics is owned by VANGUARD GROUP INC?

As of Mar 2023, VANGUARD GROUP INC holds 16.89K shares of ZyVersa Therapeutics (ZVSA), compromising 0.19% of the company, valued at $32.6M.

What percentage of ZyVersa Therapeutics is owned by WINTHROP ADVISORY GROUP LLC?

WINTHROP ADVISORY GROUP LLC is the third largest holder of ZyVersa Therapeutics. The company owns 13.36K of the company's shares outstanding (worth $26K).